EBV-Associated Lymphoma Consortium Annual Meeting (Abstract)

Abstract Submission

Submission information

Submission Number: 11

Submission ID: 150967

Submission UUID: 0b3b3924-8791-41ae-b8e5-bdab6009af25

Submission URI: /nci/ealv/venue/abstract

Submission Update: /nci/ealv/venue/abstract?token=s9VHZ_l2q0qifF5EYZJ7U_7lg8VqelukZYgI2aSd6Sw

Created: Thu, 09/04/2025 - 18:11

Completed: Thu, 09/04/2025 - 18:11

Changed: Thu, 09/04/2025 - 18:11

Remote IP address: 10.208.24.100

Submitted by: Anonymous

Language: English

Is draft: No

Webform: EBV-Associated Lymphoma Consortium Annual Meeting (Abstracts)

Submitted to: EBV-Associated Lymphoma Consortium Annual Meeting (Abstract)

OMB No.: 0925-0740
Expiration Date: 9/30/2025

Public reporting burden for this collection of information is estimated to average 60 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-0740). Do not return the completed form to this address.

Presenter Information

Please enter information for the person who will be the primary presenter/speaker/author.

First Name

Middle Initial

Last Name

Degree(s)

Please use the following formatting for these degrees: M.D. Ph.D. MPH

Position/Title/Career Status

Organization

Organization City/Town

Please provide a contact email for conference organizers to reach you.

Abstract Information

Abstract Keywords

Up to five keywords of your choice

Abstract Title

Abstract Summary

Introduction: EBV DNA derived from tumors is consistently methylated with unique methylation profiles. In contrast, virion DNA is never methylated. This project seeks to study the relationship between the EBV epigenome and EBV transcriptome in EBV(+) lymphoma in people with HIV (PWH). We will characterize EBV methylation in cell-free DNA (cfDNA) from plasma and saliva to define methylation patterns in different disease states in order to develop novel diagnostics for HIV-associated lymphoma.
Methods: EBV methylation was evaluated by a bead-based methyl-DNA binding protein capture of the W promoter and bisulfite sequencing of the viral genome (bsEBV-seq). Plasma samples from PWH with Hodgkin lymphoma (HL, n=12) or Plasmablastic lymphoma (PBL, n=21) were analyzed by the bead-based method. Thirty-two samples (tissue biopsy, plasma, and saliva) underwent bsEBV-seq. Lastly, cfDNA from 71 plasma samples and 44 matched saliva samples from PWH without EBV(+) lymphoma were evaluated for the presence of EBV. 
Results: Bead-based methylation of Wp shows hypermethylation in HL (median 97%, 83-98%) and variable methylation in PBL (median 47%, 3-96%). bsEBV-seq shows diagnosis-specific and lymphoma subtype-specific patterns of methylation. HL shows consistent methylation across the EBV genome, whereas EBV methylation is more variable in PBL. Regarding OriP, there is either no methylation of the entire region, or there is recurrent site-specific hypermethylation. When evaluating EBV in PWH without EBV(+) lymphoma, the frequency of detecting EBV is higher in saliva (94%, 44/47) than in plasma (67%, 48/71). The level of EBV is also higher in saliva (median 3.8 LogEBVcopies/mL) than in plasma (0.8 LogEBVcopies/mL). bsEBV-seq of select saliva samples show no methylation across the viral genome consistent with presence of virion DNA. 
Conclusions: Different methods of analyzing EBV methylation were applied. Findings from the EBV methylome studies will enable the development of novel plasma and saliva diagnostics for lymphoma in PWH.